Summary of Publications

TI, a dendritic cell vaccine already validated in blood cancer, was tested for the first time in a new mouse model of recurrent ovarian cancer. On its own, it triggered a strong anti-tumor immune response, suppressed tumor-promoting immune cells, and restored T cell surveillance; curbing both tumor progression and recurrence.

NationalLibrary of Medicine

Platelets can turn monocytes into functional dendritic cells within 18 hours (no cytokines needed) via direct cell contact; and these „physiological DCs“ prime tumor-specific T cells more effectively than the standard lab-made kind.

National Library of Medicine 

Dendritic cells drive antigen-specific immunity, making them a long-standing target for cancer, infectious disease, and autoimmune therapies. But producing them reliably at scale has been hard. This review covers the evolution of DC production methods (from cytokine-based to genetically engineered), the current clinical landscape of DC therapies, and emerging approaches inspired by how DCs mature naturally in the body.

National Library of Medicine 

Using a mouse-scale version of the clinical ECP device, researchers pinpointed why this widely used lymphoma therapy works: platelets convert monocytes into dendritic cells that engulf and present antigens from psoralen-damaged tumor cells, and these dendritic cells then drive CD4/CD8 T cells to attack the tumor. Since this mechanism isn’t specific to lymphoma, the findings suggest ECP could potentially be extended to solid tumors as well.

National Library of Medicine 

A 2017 expert panel (ACE) reached consensus that ECP is a dendritic-cell-based therapy that can be intentionally „polarized“ toward either immunizing (anti-cancer) or tolerizing (anti-rejection) modes rather than working as a single fixed treatment. Based on this, they called for expedited research and named six pilot trial targets: CTCL, graft-vs.-host disease, ovarian carcinoma, anti-graft cytotoxic antibodies, pemphigus vulgaris, and haplotype-mismatched stem cell transplants.

National Library of Medicine 

ECP works by using platelets to physiologically turn monocytes into dendritic cells, whose natural dual capacity to both immunize and suppress immunity likely explains why the same treatment fights lymphoma while also calming GVHD and transplant rejection. Understanding this mechanism could make ECP more potent and open it up to new cancers, autoimmune diseases, and patient-tailored use.

National Library of Medicine

ECP triggers monocytes to rapidly (within a day, no cytokines needed) mature into functional, synchronized dendritic cells, driven by a distinct, reproducible gene-expression signature affecting over 1,100 genes — and this happens the same way regardless of disease state, in both healthy subjects and patients. This suggests ECP’s clinical benefits stem largely from these newly generated dendritic cells, and that ECP could eventually serve as a general platform for producing therapeutic DCs.

National Library of Medicine

In a 60-patient trial of heart transplant recipients, adding photopheresis to standard triple-drug immunosuppression significantly reduced acute rejection episodes (0.91 vs. 1.44 per patient) without raising infection rates, and even cytomegalovirus detection was lower in the photopheresis group — though survival and time-to-first-rejection didn’t differ between groups.

National Library of Medicine

In this landmark trial, extracorporeal photochemotherapy — UV-A activating methoxsalen in a lymphocyte-enriched blood fraction before reinfusion — helped 27 of 37 patients with treatment-resistant cutaneous T-cell lymphoma, cutting skin involvement by an average of 64% over about 22 weeks, including cases resistant to standard chemotherapy, and without chemotherapy’s typical side effects like bone marrow suppression or hair loss.

National Library of Medicine